UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico

The American journal of tropical medicine and hygiene, 2015-09, Vol.93 (3), p.441-453

2015

Volltextzugriff (PDF)

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

Journal of acquired immune deficiency syndromes (1999), 2006-12, Vol.43 (5), p.509-515

2006

Volltextzugriff (PDF)

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

Human vaccines & immunotherapeutics, 2022-11, Vol.18 (5), p.2046960-2046960

2022

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

The New England journal of medicine, 2015-08, Vol.373 (8), p.705-713

2015

Volltextzugriff (PDF)

Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19532-n/a

2014

Volltextzugriff (PDF)

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Journal of acquired immune deficiency syndromes (1999), 2007-10, Vol.46 (2), p.125-133

2007

Volltextzugriff (PDF)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

PloS one, 2018-10, Vol.13 (10), p.e0205368-e0205368

2018

Volltextzugriff (PDF)

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial

Antiviral therapy, 2019-01, Vol.24 (6), p.425-435

2019

Volltextzugriff (PDF)

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

Journal of acquired immune deficiency syndromes (1999), 2009-06, Vol.51 (2), p.163-174

2009

Volltextzugriff (PDF)

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

Journal of acquired immune deficiency syndromes (1999), 2009-11, Vol.52 (3), p.350-356

2009

Volltextzugriff (PDF)

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)

Journal of acquired immune deficiency syndromes (1999), 2012-09, Vol.61 (1), p.73-77

2012

Volltextzugriff (PDF)

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

The New England journal of medicine, 2015-01, Vol.372 (2), p.113-123

2015

Volltextzugriff (PDF)

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1429-1441

2008

Volltextzugriff (PDF)

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

2008

Volltextzugriff (PDF)

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

AIDS (London), 2010-01, Vol.24 (1), p.55-65

2010

Volltextzugriff (PDF)

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

Annals of internal medicine, 2010-09, Vol.153 (6), p.349

2010

Volltextzugriff (PDF)

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

The New England journal of medicine, 1999-12, Vol.341 (25), p.1865-1873

1999

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

AIDS research and human retroviruses, 2012-05, Vol.28 (5), p.437-446

2012

Volltextzugriff (PDF)

Estimation of Survival in Patients with Glioblastoma Using an Online Calculator at a Tertiary-Level Hospital in Mexico

Curēus (Palo Alto, CA), 2022-12

2022

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

The Lancet infectious diseases, 2024-10, Vol.24 (10), p.1141-1150

2024

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

The lancet HIV, 2018-05, Vol.5 (5), p.e211-e220

2018

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

The lancet HIV, 2020-01, Vol.7 (1), p.e16-e26

2020

Volltextzugriff (PDF)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795

PloS one, 2018-10, Vol.13 (10), p.e0205368

2018

Volltextzugriff (PDF)

636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S420-S421

2021

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(43)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

Estimation of Survival in Patients with Glioblastoma Using an Online Calculator at a Tertiary-Level Hospital in Mexico

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795

636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)

Suchergebnisse filtern